T-STM : Spatio Temporal Modeling of the Tumor-Microenvironment for in silico Testing of Immunomodulatory Drug Combinations for Enhanced Triple Negative Breast Cancer Immunotherapy
ISEF · 2024 Computational Biology and Bioinformatics Fourth Award
Overview
Breast cancer affects 2.3 million women annually with the five-year survival rate for Triple-negative-breast-cancer (TNBC) being 12%. Current immunotherapy treatments are effective only in 25% patients as the multiple immunosuppressive mechanisms of the Tumor-microenvironment (TME) are not understood. T-STM is the first of its kind multi-agent, Spatial-temporal-modeling based simulation of the TNBC TME. T-STM uses a novel hybrid approach with discrete models to characterize tumor, stromal and immune interactions; driven by tumor and patient-specific metabolic profiles, signaling and immune infiltration patterns derived from TCGA(The-Cancer-Genome-Atlas) data along with partial-differential-equations for modeling nutrient diffusion and the multiple immunosuppressive pathways in the TME. Simulation results were successfully validated with TCGA histopathological immunophenotypes matching and cell fraction histograms showing high correlation with r values between 0.785 and 0.91. Simulations run on 100 TNBC datasets for 150 days, testing for optimal combinations of immunomodulatory drugs showed best tumor reduction for the combination of TLR9 agonist with P13k, mTOR and IDO inhibitors combined with LAG3 and PDL1 blockade with an average of 80% reduction in tumor cells across 40 datasets. T-STM shows best immune-efficacy with low stroma and high tumor-infiltrating-lymphocytes scenario validated by Kaplan–Meier survival curves (hazard ratio 0.308 , P = 0.0219) with stromal permeability boost increasing immune response. T-STM can potentially shorten the drug development cycles through identification of combination inhibitor therapies based on simulated remission rates to create customized therapeutics for enhanced cancer immunotherapy with reduced costs.
Awards (1)
- Fourth Award of $500 $500
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2021
ImmunoNet: A Novel in-silico Platform to Personalize Immunotherapy for Breast Cancer Treatment
ISEF · 2026
TMEInsight: Elucidating Patient-Specific Immune-Pathway Crosstalk via Deep Learning to Foreshadow Tumor Progression
ISEF · 2023
Developing and Utilizing a Whole-Cell Mathematical Model of IL-6 in Triple-Negative Breast Cancer: Predicting Cell Behavior and Targeted Anti-Tumorigenic Drug Interactions
ISEF · 2025
Single-Cell Analysis Based Identification of Unique Markers and Metastasis Mechanism in Triple-Negative Breast Cancer
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair